http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010529086-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2008-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010529086-A |
| titleOfInvention | Piperidine / piperazine derivatives |
| abstract | The present invention encompasses any stereochemically isomeric form of formula (I) [Chemical 1] [In the formula, A represents CH or N, X represents O or NR x , the broken line represents an arbitrary bond when A represents a carbon atom, Y represents a direct bond, —NR x —C (═O ) -, - C (= O ) -NR x -, - NR x -C (= O) -Z -, - NR x -C (= O) -Z-NR y -, - NR x -C (= O) —Z—NR y —C (═O) —, —NR x —C (═O) —Z—NR y —C (═O) —O—, —NR x —C (═O) —Z —O—, —NR x —C (═O) —Z—O—C (═O) —, —NR x —C (═O) —Z—C (═O) —, —NR x —C ( ═O) —Z—C (═O) —O—, —NR x —C (═O) —O—Z—C (═O) —, —NR x —C (═O) —O—Z— C (= O) -O -, - NR x -C (= O) -O-Z-O-C (= O) -, - NR x - (= O) -Z-C ( = O) -NR y -, - NR x -C (= O) -Z-NR y -C (= O) -NR y -, - C (= O) -Z —, —C (═O) —Z—O—, —C (═O) —NR x —Z—, —C (═O) —NR x —Z—O—, —C (═O) —NR x— Z—C (═O) —, —C (═O) —NR x —Z—O—C (═O) —, —C (═O) —NR x —O—Z—, —C ( = O) -NR x -Z-NR y -, - C (= O) -NR x -Z-NR y -C (= O) -, - C (= O) -NR x -Z-NR y - Represents C (═O) —O—, wherein R 1 is optionally substituted C 1-12 alkyl; C 2-6 alkenyl; C 2-6 alkynyl; C 3-6 cycloalkyl; aryl 1 ; aryl 1 C 1-6 alkyl; Het 1; or Het It represents a C 1-6 alkyl, provided that Y is -NR x -C (= O) -Z -, - NR x -C (= O) -Z-NR y -, - NR x -C (= O) —ZC (═O) —NR y —, —C (═O) —Z—, —NR x —C (═O) —Z—NR y —C (═O) —NR y —, —C When (═O) —NR x —Z—, —C (═O) —NR x —O—Z— or —C (═O) —NR x —Z—NR y —, R 1 is also R 2 and R 3 are each independently hydrogen; hydroxyl; carboxyl; halo; C 1-6 alkyl; polyhaloC 1-6 alkyl; optionally C 1-4 alkyloxy, provided that hydrogen may be represented. in an optionally substituted C 1-6 alkyloxy; C 1-6 alkylthio; polyhaloC C 1-6 alkyloxy; C 1-6 Arukiruo Aryloxycarbonyl, cyano, aminocarbonyl; mono- - or di (C 1-4 alkyl) aminocarbonyl; C 1-6 alkylcarbonyl; nitro; amino; mono- - or di (C 1-4 alkyl) amino; -S (= O) represents p- C 1-4 alkyl, R 4 is hydrogen; hydroxyl; carboxyl; halo; C 1-6 alkyl; polyhaloC 1-6 alkyl; optionally substituted C 1-6 alkyloxy C 1-6 alkylthio; polyhaloC 1-6 alkyloxy; C 1-6 alkyloxycarbonyl (where C 1-6 alkyl may be optionally substituted); cyano; C 1-6 alkylcarbonyl ; nitro; amino; mono- - or di (C 1-4 alkyl) amino; C 1-4 alkylcarbonylamino; -S (= O p -C 1-4 alkyl; R 6 R 5 N-C (= O) -; R 6 R 5 N-C 1-6 alkyl; C 3-6 cycloalkyl; aryl; aryloxy; aryl C 1-4 Alkyl; aryl-C (═O) —C 1-4 alkyl; aryl-C (═O) —; Het; HetC 1-4 alkyl; Het-C (═O) —C 1-4 alkyl; Het-C (= O) -; Het- O- to represent, R 9 is hydrogen; represents a C 1-4 alkyl substituted with hydroxyl]; halo; C 1-4 alkyl Or a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to a method for producing the compound, to the use of the compound as a medicament as well as to a pharmaceutical composition comprising the compound. [Selection figure] None |
| priorityDate | 2007-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 545.